Contact Dissolution for Gallstones — CPB 0509 | AETNA Coverage Update

TL;DR: Aetna updated CPB 0509 for contact dissolution of gallstones, effective November 27, 2025. The policy maintains a full non-coverage position — every agent used in this procedure remains classified as experimental, investigational, or unproven.

If your team has ever billed or considered billing contact dissolution for gallstones under Aetna, this policy update is a hard stop. CPB 0509 covers the full K80.xx cholelithiasis code range — 82 ICD-10 diagnosis codes across every gallstone presentation — and Aetna's position on treatment via direct solvent dissolution hasn't softened. No FDA-approved agents, no coverage. That's the policy in one sentence.

Quick-Reference Table

Aetna Contact Dissolution for Gallstones Coverage Criteria and Medical Necessity Requirements 2025

The Aetna contact dissolution coverage policy under CPB 0509 is straightforward: there is no coverage. Aetna does not recognize contact dissolution — also called direct solvent dissolution or litholysis — as medically necessary for gallstone treatment. Full stop.

Medical necessity requires that a treatment be safe, effective, and supported by clinical evidence. None of the three agents used in contact dissolution — ethyl propionate, isopropyl acetate, and methyl tertiary butyl ether (MTBE) — has received FDA approval for gallstone treatment. That's the core of Aetna's medical necessity denial rationale.

The clinical argument here isn't subtle. FDA non-approval isn't a technicality. It's Aetna's primary basis for saying the safety and effectiveness of these agents hasn't been established. Until that changes, prior authorization won't save a claim for this procedure. There's nothing to authorize.

Editorial note: CPB 0509 contains no prior authorization language. The guidance below reflects general billing practice context for procedures classified as experimental, investigational, or unproven — not language derived from this policy.

If your billing team is fielding questions from providers about whether prior authorization could open the door to reimbursement under this policy, the answer is no. Prior auth for a procedure classified as experimental, investigational, or unproven doesn't change the coverage status. It's the same outcome with extra paperwork.

Aetna Contact Dissolution Exclusions and Non-Covered Indications

This is the core of CPB 0509. Aetna classifies contact dissolution for gallstones as experimental, investigational, or unproven across the board — not in some contexts, not for some patients. Every indication.

The three agents explicitly named in the policy are:

None of these agents is FDA-approved for gallstone dissolution. Aetna cites both the lack of FDA approval and the absence of established safety and effectiveness data. That's a two-factor disqualification.

This isn't a situation where clinical documentation of patient severity might flip the coverage decision. The policy language covers all gallstone presentations across the K80.xx diagnosis range. It doesn't matter whether the patient has any specific gallstone presentation. The treatment approach itself is what Aetna rejects.

This pattern mirrors how Aetna and other major payers handle other experimental designation policies. When FDA approval is the missing piece, payers rarely budge on individual claims — even with strong medical records. If a provider at your practice is pursuing this approach, loop in your compliance officer and the treating physician before any billing occurs.

Coverage Indications at a Glance

Aetna Contact Dissolution Billing Guidelines and Action Items 2025

The effective date of November 27, 2025 is already here. If you haven't audited your charge capture for contact dissolution procedures, do it now.

CPT, HCPCS, and ICD-10 Codes for Contact Dissolution for Gallstones Under CPB 0509

The policy data for CPB 0509 does not list specific CPT or HCPCS procedure codes. Aetna's policy language addresses the procedure by name and agent — not by CPT code — because no CPT code exists specifically for gallstone contact dissolution using these experimental solvents. If your coding team is attempting to bill this under an unlisted procedure code, expect a claim denial under the experimental/investigational determination.

The full ICD-10-CM diagnosis code range covered by this policy is the K80 (Cholelithiasis) family. Every subcategory is included.

ICD-10-CM Diagnosis Codes — Cholelithiasis (CPB 0509)

The source policy lists all 82 codes in the K80.xx family under the single description "Cholelithiasis." No granular sub-descriptions are provided in CPB 0509. The table below reflects the source exactly.

The source policy references 82 total ICD-10-CM codes. Two codes beyond K80.81 were not fully provided in the source data. Review the full CPB 0509 policy document at Aetna's clinical policy library for the complete list.